Head and Neck Cancer Registry (LORHAN)
Overview
The primary objective of this study is to describe, in detail, patterns of care for head and neck carcinoma patient
Full Title of Study: “Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy Other Than Surgical Resection Alone for Newly Diagnosed Head and Neck Cancer”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 2011
Interventions
- Other: Therapy for head and neck cancer
- radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
Arms, Groups and Cohorts
- Patients with head and neck cancer
Clinical Trial Outcome Measures
Primary Measures
- Patterns of care for head and neck cancer
- Time Frame: up to 10 years
Secondary Measures
- Overall survival by treatment regimen
- Time Frame: study entry to death from any cause or to end of study
- Determine the incidence and severity of major dose-limiting and other important treatment toxicities
- Time Frame: up to 10 years
- Identify supportive care received for managing nutrition, pain, nausea and other complications
- Time Frame: up to 10 years
- tumor control by treatment regimen
- Time Frame: study entry to progressive disease
Participating in This Clinical Trial
Inclusion Criteria
- Pathologically (histologically or cytologically) confirmed new diagnosis of carcinoma involving the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or neck node metastasis from unknown origin – Scheduled to receive radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy – Written informed consent Exclusion Criteria:
- Registry participation does not exclude participation in clinical trials. – Patients scheduled to receive or who have received surgery are eligible for Registry participation as long as they are also scheduled to receive medical therapy.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Eli Lilly and Company
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Mednet Solutions, Study Director, MedNet Solutions
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.